[{"id":"b1ea3548-1357-4919-8863-692b030155e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03067935","created_at":"2022-02-12T17:11:48.013Z","updated_at":"2024-07-02T16:37:10.634Z","phase":"","brief_title":"Individual Patient Expanded Access-Glembatumumab Vedotin","source_id_and_acronym":"NCT03067935","lead_sponsor":"Celldex Therapeutics","biomarkers":" GPNMB","pipe":" | ","alterations":" GPNMB expression • GPNMB overexpression","tags":["GPNMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPNMB expression • GPNMB overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glembatumumab vedotin (CDX-011)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2018-05-21"}]